Northwell Health/Center for Advanced Medicine

Summary

Northwell Health/Center for Advanced Medicine is a medical facility located in New Hyde Park, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Cancer, Ovarian Cancer and other specialties. Northwell Health/Center for Advanced Medicine is involved with conducting 148 clinical trials across 234 conditions. There are 38 research doctors associated with this hospital, such as Veena John, MD, Shaheer Khan, Thomas P. Bradley, and Anuj Goenka, MD.

Top PIs

Clinical Trials running at Northwell Health/Center for Advanced Medicine

Prostate Cancer

Kidney Cancer

Lung Cancer

Bladder Cancer

Breast Cancer

Esophageal cancer

Cancer

Bladder Carcinoma

Pancreatic Cancer

Oropharyngeal Carcinoma

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Recruiting

2 awards

Phase 3

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

Recruiting

2 awards

Phase 3

10 criteria

Radiation Therapy

for Prostate Cancer

This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?

Recruiting

2 awards

Phase 3

5 criteria